Gilead Sciences, Inc. $GILD Shares Sold by Parallax Volatility Advisers L.P.

Parallax Volatility Advisers L.P. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 72.6% during the 2nd quarter, Holdings Channel reports. The firm owned 8,057 shares of the biopharmaceutical company’s stock after selling 21,313 shares during the quarter. Parallax Volatility Advisers L.P.’s holdings in Gilead Sciences were worth $1,018,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in GILD. Magnolia Capital Advisors LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $382,000. Strategic Global Advisors LLC purchased a new stake in Gilead Sciences during the 2nd quarter worth about $2,222,000. Caisse de depot et placement du Quebec acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $263,215,000. Man Group plc acquired a new position in Gilead Sciences in the 2nd quarter valued at $156,055,000. Finally, Western Wealth Management LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter worth about $502,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 0.5%

GILD stock opened at $148.09 on Thursday. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a market capitalization of $183.62 billion, a price-to-earnings ratio of -55.46 and a beta of 0.32. The firm’s 50-day moving average is $133.31 and its two-hundred day moving average is $136.58. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period last year, the firm posted $2.01 earnings per share. The business’s revenue was up 10.6% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post -0.5 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $138.36, for a total value of $415,080.00. Following the sale, the chief financial officer owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. The trade was a 1.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the sale, the insider owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. This trade represents a 19.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 87,000 shares of company stock valued at $11,562,960 in the last quarter. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GILD shares. Rothschild & Co Redburn cut their price objective on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Truist Financial lowered their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Barclays dropped their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Finally, Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Twenty-four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.